Skip to main content
. 2013 Mar 22;5(6):1948–1954. doi: 10.3892/ol.2013.1269

Figure 4.

Figure 4

BRCA2 confers sensitivity to NOC treatment. The sensitivity to (A) NDEA, (B) NDELA and (C) NDPA was determined using a clonogenic survival assay in vector- and siBRCA2-transfected SGC7901 cells. BRCA2, breast cancer susceptibity gene 2; NOC, N-nitroso compound; NDEA, N-nitrosodiethylamine; NDELA, N-nitrosodiethanolamine; NDPA, N-nitrosodipropylamine; siBRCA2, small interfering BRCA2 RNA.